New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:08 EDTIMMUImmunomedics announces presentation of epratuzumab data
Immunomedics announced that scientific data on epratuzumab, an investigational therapy for the treatment of systemic lupus erythematosus, also known as lupus, will be presented at the European League Against Rheumatism 2014 Annual Congress to be held in Paris, France. Epratuzumab is an investigational medicine in Phase III clinical development for the treatment of SLE. Epratuzumab is a monoclonal antibody that targets CD22. Epratuzumab is not approved for the treatment of SLE by any regulatory authority worldwide. Immunomedics has granted UCB exclusive worldwide rights to develop, market, and sell epratuzumab for all autoimmune disease indications.
News For IMMU From The Last 14 Days
Check below for free stories on IMMU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
06:15 EDTIMMUImmunomedics files $130M mixed securities shelf
Subscribe for More Information
September 12, 2014
12:20 EDTIMMUImmunomedics management to meet with Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use